Norges Bank’s ImmunityBio IBRX Stock Holding History

Norges Bank’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-9,100	Closed	-$104K	–	2250
2015 Q3	$104K	Buy	+9,100	New	+$199K	﹤0.01%	2255

Other funds holding IBRX

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank's IBRX Position: Q4 2015 in Review

Norges Bank sold out of ImmunityBio (IBRX) in Q4 2015, closing a stake of 9,100 shares — an estimated $104K sold.

Norges Bank first reported a position in IBRX in Q3 2015 and held it in 1 quarter. The position peaked at $104K in Q3 2015. 61 funds tracked by Wall St. Rank hold IBRX as of Q4 2015.

Norges Bank reported no remaining ImmunityBio position as of Q4 2015 after selling out during the quarter.
Norges Bank sold 9,100 ImmunityBio shares in Q4 2015, an estimated $104K.
Norges Bank first reported a position in ImmunityBio in Q3 2015 and held it in 1 quarter.
Norges Bank's ImmunityBio position peaked at $104K in Q3 2015.
61 funds tracked by Wall St. Rank held ImmunityBio as of Q4 2015.

Based on Norges Bank's 13F filing for Q4 2015, filed 10 Feb 2016.